Skip to main content

Table 1 Clinical characteristics according to grade of steatosis based on liver fat fraction measured by MRI

From: Association between hepatic steatosis and fibrosis with measures of insulin sensitivity in patients with severe obesity and type 2 diabetes - a cross-sectional study

 

All

No or low grade steatosisa

Medium to high gradea

P-value

N (%)

100 (100)

25 (25)

75 (75)

 

Liver fat fraction, % (range)

19.1 (−5.5–43.3)

4.7 (− 5.5–9.9)

24.2 (10.7–43.3)

< 0.001

Age, years

47.5 (9.7)

49.3 (8.8)

46.9 (10.0)

0.297

Gender, female (%)

65

19 (76)

46 (61)

0.183

Metabolic syndrome, n (%)

98 (98)

25 (100)

73 (97)

0.409

White ethnicity, n (%)

97 (97)

24 (96)

73 (97)

0.735

Alcohol consumption, units a week

1.0 (1.4)

0.7 (1.0)

1.1 (1.5)

0.229

Antropometrics

 BMI, kg/m2

42.0 (5.3)

41.6 (5.8)

42.1 (5.1)

0.688

 FFM, kg

66.7 (13.9)

64.5 (11.9)

67.4 (14.5)

0.364

 FM, kg

58.7 (12.7)

58.4 (13.6)

58.8 (12.5)

0.886

 Waist circumference, cm

127.8 (11.9)

126.3 (13.4)

128.2 (11.4)

0.489

Glucose homeostasis

 Fasting glucose, mmol/L

12.1 (4.6)

12.8 (5.2)

11.8 (4.4)

0.329

 HbA1c, mmol/mol

66.2 (18.7)

65.5 (13.0)

66.5 (20.4)

0.831

 Fasting insulin, pmol/L

199 (133)

159 (129)

212 (132)

0.079

 Fasting C-peptide, pmol/L

1600 (493)

1277 (554)

1700 (430)

< 0.001

 HOMA2S, %

21.8 (8.2)

26.3 (11.0)

20.4 (6.6)

0.002

 Matsuda ISI

1.6 (0.9)

2.2 (1.3)

1.5 (0.7)

< 0.001

 MinMod SI, (mu/l)−1 x min− 1

0.86 (0.90)

0.87 (0.69)

0.86 (0.95)

0.981

 Diabetes duration, years

6.7 (6.1)

10.4 (7.5)

5.5 (5.1)

< 0.001

 Antidiabetic medication, n (%)

89 (89)

23 (92)

66 (88)

0.580

Liver status

 Alanine aminotransferase (U/L)

38.5 (20.6)

26.2 (13.0)

42.6 (21.1)

< 0.001

 Aspartate aminotransferase (U/L)

27.7 (12.5)

21.8 (8.8)

29.7 (12.9)

0.006

 AST/ALT ratio

0.79 (0.26)

0.89 (0.27)

0.75 (0.24)

0.027

 ƴ-Glutamyltransferase (U/L)

56.1 (37.8)

43.1 (28.7)

60.4 (39.6)

0.048

 ELF-score

8.46 (0.84)

8.37 (1.04)

8.49 (0.77)

0.551

 Fatty Liver Index

52.6 (25.8)

43.5 (27.1)

55.6 (24.8)

0.041

 NAFLD Fibrosis score

−0.025 (0.922)

0.082 (0.966

−0.061 (0.911)

0.505

Cardiovascular risk factors

 Total cholesterol, mmol/L

4.4 (0.9)

4.3 (0.7)

4.5 (0.9)

0.421

 LDL cholesterol, mmol/L

2.5 (0.8)

2.4 (0.6)

2.5 (0.8)

0.482

 HDL cholesterol, mmol/L

1.0 (0.2)

1.1 (0.2)

1.0 (0.2)

0.007

 Triglycerides, mmol/L

2.1 (1.3)

1.7 (0.7)

2.3 (1.4)

0.065

 Systolic BP, mmHg

132.3 (14.9)

136.8 (19.8)

130.7 (12.6)

0.078

 Diastolic BP, mmHg

84.5 (7.1)

84.9 (7.0)

84.4 (7.2)

0.766

 Antihypertensives, n (%)

65 (65)

20 (80)

45 (60)

0.069

 Lipid-lowering drugs, n (%)

46 (46)

15 (60)

31 (41)

0.105

  1. Data are presented as n (%) and mean (SD). Liver fat fraction (LFF) was estimated with the modified Dixon method calculating the percentage of liver fat using magnetic resonance imaging (MRI). No or low grade hepatic steatosis was defined in patients with values below or equal to the 25th percentile (≤10%) of LFF at baseline. Two-sample t-test with equal variance for continues variables and Pearson Chi-squared for categorical variables. MinMod SI, n = 83; ELF, n = 98; Matsuda ISI, n = 96; C-peptide, n = 98
  2. FFM Fat free mass, FM Fat mass
  3. aNo or low grade hepatic steatosis was defined in patients with values below or equal to the 25th percentile (≤ 10%) of LFF at baseline, while medium to high grade steatosis was defined as > 10%
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us